BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Pfizer  Limited  submitted  on  27  February  2003  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Lyrica, 
through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  20  November  2002,  this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
B. van Zwieten-Boot  
Co-Rapporteur: C. Sampaio 
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 24 March 2003. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 6 June 2003 . 
The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 18 June 
2003 . 
During the meeting on 22-24 July 2003, the CPMP agreed on the consolidated List of Questions 
to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  
25 July 2003. 
The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  14 
October 2003. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CPMP members on  21 November 2003. 
During the CPMP meeting on 16-18 December 2003, the CPMP agreed on a list of outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant. 
The  applicant  submitted  the  responses  to  the  CPMP  list  of  outstanding  issues  on  14  January 
2004. 
The Rapporteurs circulated a Joint Assessment Report on the applicant’s responses to the List of 
outstanding issues to all CPMP members on  13 February 2004. 
During  the  CPMP  meeting on  24-26 February 2004,  the  Committee and the Applicant  agreed 
that there was no need for an Oral Explanation. 
During the meeting on  23-25 March 2004, the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Lyrica on 25 March 2004. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  The  European  Union,  to  the 
European Commission, which adopted corresponding Decision on 6 July 2004. 
1/1
@EMEA 2004 
 
 
 
 
 
